MAGEA3 and melanoma: Phase III trials of the MAGE-A3 vaccine in NSCLC and melanoma were also terminated prematurely due to futility, suggesting that MAGE-A3 vaccination is unlikely to be an optimal immunotherapeutic strategy [17,19].